Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1542
  • Home
  • Print this page
  • Email this page
This article has been cited by
1Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review
Taylor Halsey,Gabriel Ologun,Jennifer Wargo,Robert R. Jenq
Seminars in Hematology.2020;57(1)13
[DOI]
2

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date

Iris Y Sheng,Moshe C Ornstein
Cancer Management and Research.2020;Volume 12(1)4871
[DOI]
3Classical Examples of the Concept of the ASIA Syndrome
Vânia Borba,Anna Malkova,Natalia Basantsova,Gilad Halpert,Laura Andreoli,Angela Tincani,Howard Amital,Yehuda Shoenfeld
Biomolecules.2020;10(10)1436
[DOI]
4Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Silvia Vivarelli,Luca Falzone,Caterina Maria Grillo,Giuseppa Scandurra,Francesco Torino,Massimo Libra
Cancers.2020;12(8)2237
[DOI]
5Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities
Pak Yui Fong,Shing Chuen Chow,Bernard Ming Hong Kwong,Charlene Cheuk Lam Lau,Christy Yik Ching Lau,Athena Hoi Ting Lee,Ha Ying Nip,Cheuk Yin Wong,Benedict Tsz Hin Yan,Ho Yin Chung
Journal of Clinical Rheumatology and Immunology.2020;20(01)25
[DOI]
6Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non–Small Cell Lung Cancer
Ninh M. La-Beck,Dung T. Nguyen,Alex D. Le,Saeed K. Alzghari,Saralinh T. Trinh
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2020;40(3)239
[DOI]
7The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events
Bradley D. Menz,Jacinta L. Johnson,Davina F. Gillard,William Chong,Michael B. Ward
Journal of Pharmacy Practice.2019;40(3)089719001987293
[DOI]
8Immune-Mediated Toxic Epidermal Necrolysis
Dinesh Keerty,Viktoriya Koverzhenko,Dalila Belinc,Katie LaPorta,Elizabeth Haynes
Cureus.2020;40(3)089719001987293
[DOI]
9Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs
Tyler C. Vandivort,David B. Horton,Steven B. Johnson
Journal of Clinical and Translational Science.2020;40(3)1
[DOI]
10Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
Ronald Anderson,Annette J. Theron,Bernardo L. Rapoport
Frontiers in Immunology.2019;10(3)1
[DOI]
11Atypical extended immune-related neutropenia in patient treated with pembrolizumab
Pierre-Antoine Laurain,Térence Landrin,Sami Souidi,Philippe Beuzeboc,Florian Scotté
European Journal of Cancer.2020;130(3)269
[DOI]
12Angioedema late in the course of adjuvant nivolumab therapy for melanoma
Atul Ratra,Constantin A Dasanu
Journal of Oncology Pharmacy Practice.2020;26(4)1019
[DOI]
13Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers
Tomomi W Nobashi,Yuko Nishimoto,Yujiro Kawata,Hidetaka Yutani,Masaki Nakamura,Yuichi Tsuji,Atsushi Yoshida,Akihiko Sugimoto,Takayuki Yamamoto,Israt S Alam,Satoshi Noma
The British Journal of Radiology.2020;93(1115)20200409
[DOI]
14Management of immune checkpoint inhibitor-related rheumatic adverse events
Jiaxin Zhou,Hanping Wang,Xiaoxiao Guo,Qian Wang,Lian Duan,Xiaoyan Si,Li Zhang,Xiaowei Liu,Yue Li,Wen Zhang,Li Zhang
Thoracic Cancer.2020;11(1)198
[DOI]
15Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report
El Ali Ziad,Verset Laurine
Clinical Oncology and Research.2019;11(1)1
[DOI]
16Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis
Andrea Pagan,Yadis M Arroyo-Martinez,Ankita Tandon,Carlos Bertran-Rodriguez,Jeffrey Gill
Cureus.2020;11(1)1
[DOI]
17Durvalumab in cancer medicine: a comprehensive review
Juliana Alvarez-Argote,Constantin A. Dasanu
Expert Opinion on Biological Therapy.2019;19(9)927
[DOI]
18Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors
Lillian Sun,Joshua Arbesman,Melissa Piliang
Archives of Dermatological Research.2020;19(9)927
[DOI]
19Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Massimo Ralli,Andrea Botticelli,Irene Claudia Visconti,Diletta Angeletti,Marco Fiore,Paolo Marchetti,Alessandro Lambiase,Marco de Vincentiis,Antonio Greco
Journal of Immunology Research.2020;2020(9)1
[DOI]
20Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy
Dinesh Keerty,Manoj Das,Julie Hallanger-Johnson,Elizabeth Haynes
Cureus.2020;2020(9)1
[DOI]
21Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use
Rebecca N. Jerome,Meghan Morrison Joly,Nan Kennedy,Jana K. Shirey-Rice,Dan M. Roden,Gordon R. Bernard,Kenneth J. Holroyd,Joshua C. Denny,Jill M. Pulley
Drug Safety.2020;43(6)567
[DOI]
22Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
Maria V. Deligiorgi,Gerasimos Siasos,Chrysovalantis Vergadis,Dimitrios T. Trafalis
International Immunopharmacology.2020;83(6)106427
[DOI]
23Cancer immunotherapy–related adverse events: causes and challenges
Ada G. Blidner,Jennifer Choi,Tim Cooksley,Michael Dougan,Ilya Glezerman,Pamela Ginex,Monica Girotra,Dipti Gupta,Douglas Johnson,Vickie R. Shannon,Maria Suarez-Almazor,Bernardo L. Rapoport,Ronald Anderson
Supportive Care in Cancer.2020;28(12)6111
[DOI]
24Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event
Maria V. Deligiorgi,Dimitrios T. Trafalis
International Immunopharmacology.2020;89(12)107050
[DOI]
25Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
Omid Kooshkaki,Afshin Derakhshani,Negar Hosseinkhani,Mitra Torabi,Sahar Safaei,Oronzo Brunetti,Vito Racanelli,Nicola Silvestris,Behzad Baradaran
International Journal of Molecular Sciences.2020;21(12)4427
[DOI]
26Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gall Bladder With a Mass
Nayson L Fernandes,Soujanya Sodavarapu,Sukhmine Nedopil,Nikita Mohapatra,Dinesh Vyas
Cureus.2020;21(12)4427
[DOI]
27Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells
Rhiane Moody,Kirsty Wilson,Anthony Jaworowski,Magdalena Plebanski
Cancers.2020;12(3)673
[DOI]
28Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians
Maria V Deligiorgi,Mihalis I Panayiotidis,Dimitrios T Trafalis
Immunotherapy.2020;12(7)481
[DOI]
29Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma
Katarina Hradska,Michal Kascak,Roman Hajek,Tomas Jelinek
Expert Review of Hematology.2020;13(4)375
[DOI]
30The role of combination chemo-immunotherapy in advanced non-small cell lung cancer
Danilo Rocco,Luigi Della Gravara,Ciro Battiloro,Cesare Gridelli
Expert Review of Anticancer Therapy.2019;19(7)561
[DOI]
Feedback
Subscribe

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal